All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How to understand and manage cytopenic myelofibrosis?

Sep 30, 2022
Share:
Learning objective: After reading this article, learners will be able to recall real-world data on the diagnosis, management or monitoring of patients with MF.

During the Texas MPN Workshop (TMW) 2022, the MPN Hub was pleased to speak to Prithviraj Bose, MD Anderson Cancer Center, Houston, US. We asked about understanding and managing cytopenic myelofibrosis (MF).

How to understand and manage cytopenic myelofibrosis?

Bose begins by identifying anemia and thrombocytopenia as the primary cytopenias in MF, posing challenges in the management of patients with MF. Bose notes that there are no drugs approved specifically for the improvement of cytopenias in MF and then discusses two ways to manage cytopenias.

The first approach is using agents that specifically improve cytopenias, such as luspatercept, which is being developed in phase III settings to improve anemia in patients who are on ruxolitinib and still require blood transfusion. The second approach is to use agents with multiple targets, namely cytopenias and disease-related symptoms. Pelabresib, momelotinib, pacritinib, and implications of the clinical trials investigating these agents are discussed. Bose finishes with the optimal dosing of ruxolitinib in patients with cytopenic MF.